Antibody responses after immunisation with pneumococcal polysaccharide did not correlate with the severity and frequency of infections in 22 patients with severe hypogammaglobulinaemia, when these were measured by a Farr radioimmunoassay. Five "healthy" patients with severe hypogammaglobulinaemia not only failed to make antipneumococcal polysaccharide antibody, when measured by radioimmunoassay, but also had very low or unrecordable antibody responses to Escherichia coli and failed to produce antibody when immunised with tetanus toxoid. Some of these subjects, however, did make small amounts of IgM antipneumococcal polysaccharide antibody when this was measured by an enzyme linked immunosorbent assay, while others retained some ability to produce IgM or IgA or both in their saliva.
Introduction
Hypogammaglobulinaemia is now more frequently diagnosed because of routine measurement of serum immunoglobulins in patients with recurrent infections. Nevertheless, there are still only about 300 recognised patients with clinical disease due to severe "primary" antibody deficiency in Great Britain, although there are many more with clinically milder disease due to partial deficiencies of antibody production. Secondary antibody deficiency is relatively common in patients with lymphoproliferative diseases, particularly chronic lymphatic leukaemia.1 Although patients with primary hypogammaglobulinaemia have subtle T lymphocyte abnormalities, they have normal numbers of circulating T lymphocytes and do not suffer from the opportunistic infections-for example, Pneumocystis carinii, toxoplasmosis-which characteristically occur in patients with severe cellular immunodeficiency. The major clinical problem in these patients is recurrent bronchitis due to Haemophilus influenzae, cystitis and arthritis due to mycoplasmas, and intestinal infection with giardia or campylobacters. ' The tendency to such infections is considerably reduced by treatment with pooled gammaglobulin.
Experience in managing about 150 patients with profound primary hypogammaglobulinaemia has shown that there is a very poor correlation between serum immunoglobulin concentrations and the severity of symptoms. Thus a patient with a 2, 3, 4, 6, 8, 9, 12, 14, 19, 23, 25, 51, and 56 (USA nomenclature). The vaccine (0 5 ml) was injected subcutaneously in the deltoid region; serum samples were collected before immunisation and 14 days later. All samples were kept at -20°C until the antibodies were assayed. Some of the patients were subsequently immunised with 0-5 ml adsorbed tetanus toxoid, BP 40 IU (Burroughs Wellcome), by deep subcutaneous injection, serum samples being taken before and 14 days later. For those patients receiving weekly gammaglobulin replacement therapy gammaglobulin injections were withheld for two weeks after the vaccination so as to minimise the effect of passively administered antibody.
Antibody assays-A previously described radioimmunoassay (Farr technique) was used to measure total antipneumococcal polysaccharide antibodies. 
Results
All 18 healthy controls showed a rise in antibodies to type 3 or 6A pneumococcal polysaccharide, or both, indicating that it is not necessary to measure antibodies to all the components of this vaccine when using it to test for gross abnormalities in humoral immunity (figure). The figure also shows the pneumococcal polysaccharide antibody responses in the patients with hypogammaglobulinaemia. The majority showed negligible responses to both type 3 and type 6A pneumococcal polysaccharide; only one patient with mild symptoms produced a rise in type 3 antibody to within the normal range. There was no tendency for patients with less severe symptoms to produce higher arftibody titres.
Further studies were done on six symptom free patients in subgroup 2c (who were not receiving gammaglobulin replacement therapy) to test whether they had a generalised defect in antibody production or one that was confined to producing immunoprecipitable antibody to pneumococcal polysaccharide. Five showed some evidence of haemagglutinating activity against type 3 pneumococcal polysaccharide after immunisation, although the titres were very low and the haemagglutination "equivocal" in three patients (table II) . Three of these patients showed a significant rise in IgM antibody when measured by ELISA, although none of the patients in subgroup 2c showed a significant rise in IgG antibody. Only one patient in subgroup 2c showed unequivocal evidence of haemagglutinating activity against E coli pooled antigen; and of the five who were immunised with tetanus toxoid, only one produced a significant IgM response.
The mean saliva immunoglobulin concentrations in six severely symptomatic patients in subgroup 2a were: IgG 0 3 (range 0 03-0-6), IgA 0-9 (<0 01-4 0), and IgM 0 4 (<0 01-2-1) fig/ml. The concentrations in 10 healthy or mildly symptomatic patients in subgroups 2b and 2c were: IgG 0 7 (range 0 1-4-3), IgA 0 8 (<0-01-7-4), and IgM 1 6 (<0 01-6 7) jsg/ml. Analysis by Student's t test showed no significant differences, in saliva immunoglobulin concentrations between subgroup 2a and subgroups 2b and 2c.
Discussion
This paper attempts to define the most direct way of testing for clinically significant defects in humoral immunity in patients with recurrent infections. Our results show that the interpretation of a failure to respond to certain antigens is not straightforward and that further work is needed to establish a clinically useful test. The surprising finding is that there are severely hypogammaglobulinaemic subjects who make very little antibody when test immunised but nevertheless remain in reasonably good health. These subjects fail to produce precipitable antibody after immunisation with pneumococcal polysaccharide, although some of them produce an IgM response which can be measured by a "solid phase" (ELISA) technique. This suggests that they can make only low affinity IgM antibodies, which implies that the response is clonally restricted.
The measurement of antibodies to type 3 and type 6A pneumococcal polysaccharide after immunisation by "liquid phase" radioimmunoassay is clearly unsuitable as a guide to the necessity or frequency of gammaglobulin replacement therapy in patients with hypogammaglobulinaemia. We There are likely to be other factors which determine the severity and frequency of infections in hypogammaglobulinaemic patients. Local antibody production at mucosal surfaces may vary among patients, and this possibility is supported by the presence of significant amounts of IgA or IgM or both in the saliva of four of the "healthy" hypogammaglobulinaemic patients in subgroup 2c. When analysed as a group, however, there was no significant difference in the saliva immunoglobulin concentrations between healthy or mildly symptomatic patients and those with severe symptoms. Nevertheless, possibly more refined methods for quantifying immunoglobulins and specific antibodies in saliva might be helpful in distinguishing these groups.
We have shown that a pronounced deficiency in antibody production does not necessarily lead to recurrent infections in subjects living in the relatively clean British environment. Probably some of these subjects remain in good health because they can make IgM antibody, at least to polysaccharides. We have also shown that measuring IgG or IgM antibodies to tetanus toxoid after immunisation is unlikely to be helpful in assessing the gammaglobulin requirements for hypogammaglobulinaemic patients. Testing the response to pneumococcal polysaccharide may be more useful, provided that a suitable solid phase immunoassay is used to measure IgM antibody. Now that antibodies are easy to measure with ELISA techniques, probably we shall find many clinical situations where antibody production is severely depressed despite normal concentrations of serum immunoglobulins. For example, some patients having major surgery or suffering from chronic bronchitis fail to produce antitetanus antibodies when immunised."1 12 Lymphoproliferative diseases, particularly chronic lymphatic leukaemia, are also often associated with a failure to respond to immunisation.1 The unanswered question is whether the depression of antibody production is clinically important, and whether this deficiency should be corrected with gammaglobulin replacement therapy. Carefully controlled trials will be needed to avoid treating large numbers of apparently immunodeficient patients with expensive gammaglobulin concentrates.
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